Sandoz Biosimilar Approval Answers Questions On Labeling But Not Naming – UPDATED
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Zarxio with a ‘placeholder’ name (filgrastim-sndz) that combines Neupogen’s nonproprietary name with a company-specific suffix, pending development of a naming guidance.